Many vasodilators have been tried as antianginal agents, but the reflex increase in sympathetic tone produced by these drugs necessitate their use with caution in patients with angina. In the first part of this study, captopril was given to 14 patients with angina and systolic arterial pressures of greater than 120 mm Hg. Over the short term, captopril decreased arterial blood pressure (from 110 +/- 18 to 98 +/- 18 mm Hg, p less than .01) without increasing heart rate (75 +/- 15 vs 74 +/- 15 beats/min), arterial concentrations of epinephrine (0.38 +/- 0.28 vs 0.34 +/- 0.25 nM) or norepinephrine (2.7 +/- 2.1 vs 2.8 +/- 2.1 nM), or transmyocardial norepinephrine balance (216 +/- 254 vs 146 +/- 170 p mol/min). Captopril decreased average myocardial oxygen consumption (9.7 +/- 4.1 to 8.2 +/- 2.7 ml/min, p less than .01). Given over the long term (mean 5.5 months), captopril decreased the severity of angina from NYHA classification 3.0 +/- 0.8 to 1.6 +/- 0.8. In the second part of this study, captopril was given in a prospective, randomized, double-blind, placebo-controlled study to 21 patients with stable exercise-induced angina and systolic arterial pressures greater than 120 mm Hg. Captopril increased exercise time (309 +/- 137 v...Continue Reading
In vivo validation of a thermodilution method to determine regional left ventricular blood flow in patients with coronary disease
Renin-angiotensin system inhibition in conscious dogs during acute hypoxemia. Effects on systemic hemodynamics, regional blood flows, and tissue metabolism
Interaction of angiotensin-converting enzyme inhibitors with the function of the sympathetic nervous system
The effect of angiotensin converting enzyme inhibition of coronary blood flow and hemodynamics in patients without coronary artery disease
Rationale for the choice of calcium antagonists in chronic stable angina. An objective double-blind placebo-controlled comparison of nifedipine and verapamil
Role of sympathetic nervous system activity in the blood pressure response to long-term captopril therapy in severely hypertensive patients
Sympathetic responsiveness and plasma norepinephrine during therapy of chronic congestive heart failure with captopril
Influence of tissue affinity of angiotensin-converting enzyme inhibitors on left ventricular remodeling after myocardial infarction
Cardioprotective effect of angiotensin-converting enzyme inhibitors in patients with coronary artery disease
Effects of single doses of quinapril and atenolol on autonomic nervous function and exercise capacity in healthy volunteers
Acute effects of the new angiotensin converting enzyme inhibitor ramipril on hemodynamics and carotid sinus baroreflex activity in congestive heart failure
Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition
Effects of angiotensin-converting enzyme inhibition on exercise-induced angina and ST segment depression in patients with microvascular angina
Reduction of exercise-induced myocardial ischemia during add-on treatment with the angiotensin-converting enzyme inhibitor enalapril in patients with normal left ventricular function and optimal beta blockade
Effect of captopril, an angiotensin-converting enzyme inhibitor, in patients with angina pectoris and heart failure
Management of patients with heart failure and angina: do coexistent diseases alter the response to cardiovascular drugs?
Effects of benazepril and metoprolol OROS alone and in combination on myocardial ischemia in patients with chronic stable angina
Is there a role for angiotensin-converting enzyme inhibitors in the treatment of chronic myocardial ischemia?
Long-term anti-ischemic effects of angiotensin-converting enzyme inhibition in patients after myocardial infarction. The Captopril and Thrombolysis Study (CATS) Investigators
Differential control of vascular tone and heart rate by different amino acid neurotransmitters in the rostral ventrolateral medulla of the rat
The variable effects of angiotensin converting enzyme inhibition on myocardial ischaemia in chronic stable angina
Angiotensin converting enzyme inhibition in chronic stable angina: effects on myocardial ischaemia and comparison with nifedipine
Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats
Early preventive treatment of left ventricular dysfunction following myocardial infarction: optimal timing and patient selection
Evolution of the clinical management of hypertension. Emerging role of "specific" vasodilators as initial therapy
Acute anti-ischemic effects of perindoprilat in men with coronary artery disease and their relation with left ventricular function
Failure of protective effect of captopril and enalapril on exercise and dipyridamole-induced myocardial ischemia
Angiotensin-converting enzyme inhibition, the sympathetic nervous system, and congestive heart failure. The Australian Zestril (Lisinopril) Study Group
Effects of angiotensin-converting enzyme inhibition on transient ischemia: the Quinapril Anti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial
Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.
Discover the latest cardiology research in this collection of the top cardiology journals.
Antianginal Drugs: Mechanisms of Action
Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.